Table 1.
Patient information concerning personal information, malignancy type, and treatments received.
| Code | Diagnosed cancer type | Age (range*) upon diagnosis | Therapeutic scheme | |
|---|---|---|---|---|
| Before the tumor profiling | After the tumor profiling | |||
| CYP100 | Colorectal cancer | 60–70 | (a) Xelox (b) FOLFOX |
(c) FOLFIRI and Bevacizumab |
| CYP101 | Ovarian cancer | 40–50 | (a) Carboplatin and Paclitaxel (b) Caelyx and Carboplatin (c) Carboplatin and Gemcitabine (d) Topotecan (e) Docetaxel |
(f) Caeloyx |
| CYP102 | Gastric cancer | 40–50 | (a) Xelox | (b) EOX (c) Pembrolizumab |
| CYP103 | Carcinoma of unknown primary site | 50–60 | (a) Cisplatin and Capecitabine | (b) ECX (c) Nivolumab (d) Gemcitabine and Taxol |
| CYP104 | Small cell lung cancer | 70–80 | (a) Cisplatin, Etoposide and Zometa (b) Paclitaxel and Zometa |
(c) Topotecan weekly and Zometa |
| CYP105 | Cervix adenocarcinoma | 20–30 | (a) Cisplatin and Etoposide (b) Radiotherapy/chemotherapy (c) Paclitaxel/Topotecan |
(d) Carboplatin, Paclitaxel and Bevacizumab (e) CAV |
| CYP106 | Cholangiocarcinoma | 60–70 | (a) Gemcitabine and Cisplatin (b) FOLFOX |
|
| CYP107 | Pancreatic cancer | 60–70 | (a) FOLFIRINOX (b) Gemcitabine and Abraxane (c) Gemcitabine and Abraxane |
|
| CYP108 | Non-Small Cell Lung Cancer | 60–70 | (a) Cisplatin and Pemetrexed (b) Pemetrexed maintenance (c) Carboplatin/Paclitaxel/ Bevacizumab (d) Nivolumab (Opdivo) |
|
| CYP109 | Sarcoma | 40–50 | (a) Crizotinib (oral) | (b) Alectinib (oral) (c) Alectinib and Pembrolizumab |
| CYP110 | Melanoma | 30–40 | (a) Ipilimumab (b) Pembrolizumab and Ipilimumab and Zometa x (c) Nivolumab and Ipilimumab and Zometa (d) Pembrolizumab and Ipilimumab and Zometa |
(e) TIL Adoptive cell therapy (f) Pembrolizumab and Zometa (g) Carboplatin, Paclitaxel and Pembrolizumab |
| CYP111 | Cholangiocarcinoma | 60–70 | (a) Gemcitabine and Cisplatin | |
| CYP112 | Pancreatic cancer | 40–50 | (a) Gemcitabine and Abraxane (Nab-paclitaxel) | (b) Re-challenge Gemcitabine and Abraxane |
| CYP113 | Thymoma and Thymic carcinoma | 30–40 | (a) Cyclophosphamide, Doxorubicin and Cisplatin (CAP) (b) Brachytherapy (c) CAP (d) CAP (e) Brachytherapy (f) Radiotherapy (g) Carboplatin and Etoposide |
(h) Carboplatin, Paclitaxel and Bevacizumab |
| CYP114 | Triple-negative breast cancer | 50–60 | (a) TDM1, Gemcitabine and Carboplatin | (b) TDM1, Paclitaxel and Carboplatin (c) Heceptin, Paclitaxel and Zometa (d) Capecitabin, Vinorelbine and Zometa |
| CYP115 | Leiomyosarcoma | 50–60 | (a) Lartruvo and Doxorubicin (c) Brachytherpay |
(b) Gemcitabine and Docetaxel |
| CYP116 | Cholangiocarcinoma | 60–70 | (a) Gemcitabine and Cisplatin × 6 cycles (b) Gemcitabine maintenance × 2 cycles (c) CAP-OX (Capecitabine and Oxaliplatin |
|
*
Age is shown as decade range for ensuring patient privacy.